Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

UroGen Pharma (URGN) Interest & Investment Income (2020 - 2025)

UroGen Pharma (URGN) has disclosed Interest & Investment Income for 6 consecutive years, with $903000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Interest & Investment Income fell 67.16% year-over-year to $903000.0, compared with a TTM value of $5.3 million through Dec 2025, down 38.94%, and an annual FY2025 reading of $5.3 million, down 38.94% over the prior year.
  • Interest & Investment Income was $903000.0 for Q4 2025 at UroGen Pharma, down from $979000.0 in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $2.8 million in Q4 2024 and bottomed at -$2000.0 in Q1 2022.
  • Average Interest & Investment Income over 5 years is $981157.9, with a median of $903000.0 recorded in 2025.
  • The sharpest move saw Interest & Investment Income tumbled 92.68% in 2021, then soared 31600.0% in 2023.
  • Year by year, Interest & Investment Income stood at $20000.0 in 2021, then skyrocketed by 2605.0% to $541000.0 in 2022, then skyrocketed by 184.29% to $1.5 million in 2023, then surged by 78.8% to $2.8 million in 2024, then crashed by 67.16% to $903000.0 in 2025.
  • Business Quant data shows Interest & Investment Income for URGN at $903000.0 in Q4 2025, $979000.0 in Q3 2025, and $1.3 million in Q2 2025.